- Home
- CYH vs ABSI Comparison
CYH vs ABSI Comparison
Compare CYH & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- ABSI
- Stock Information
- Founded
- CYH 1985
- ABSI 2011
- Country
- CYH United States
- ABSI United States
- Employees
- CYH N/A
- ABSI N/A
- Industry
- CYH Hospital/Nursing Management
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- ABSI Health Care
- Exchange
- CYH Nasdaq
- ABSI Nasdaq
- Market Cap
- CYH 362.0M
- ABSI 353.8M
- IPO Year
- CYH 1991
- ABSI 2021
- Fundamental
- Price
- CYH $3.50
- ABSI $2.75
- Analyst Decision
- CYH Hold
- ABSI Strong Buy
- Analyst Count
- CYH 8
- ABSI 5
- Target Price
- CYH $4.02
- ABSI $8.40
- AVG Volume (30 Days)
- CYH 3.4M
- ABSI 2.5M
- Earning Date
- CYH 04-23-2025
- ABSI 05-13-2025
- Dividend Yield
- CYH N/A
- ABSI N/A
- EPS Growth
- CYH N/A
- ABSI N/A
- EPS
- CYH N/A
- ABSI N/A
- Revenue
- CYH $12,653,000,000.00
- ABSI $4,534,000.00
- Revenue This Year
- CYH N/A
- ABSI $158.58
- Revenue Next Year
- CYH $4.15
- ABSI $93.12
- P/E Ratio
- CYH N/A
- ABSI N/A
- Revenue Growth
- CYH 1.05
- ABSI N/A
- 52 Week Low
- CYH $2.24
- ABSI $2.01
- 52 Week High
- CYH $6.29
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- CYH 74.92
- ABSI 42.92
- Support Level
- CYH $2.77
- ABSI $2.85
- Resistance Level
- CYH $2.94
- ABSI $2.94
- Average True Range (ATR)
- CYH 0.21
- ABSI 0.19
- MACD
- CYH 0.11
- ABSI -0.03
- Stochastic Oscillator
- CYH 92.06
- ABSI 14.13
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.